Onconetix, Inc. (ONCO) Income Statement
ONCO 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsONCO revenue and net income
Where ONCO's revenue goes
2025Each bar shows an amount and its share of revenue. ONCO kept −1,721.0% of revenue as net income.
ONCO profit margins
ONCO growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −67.7% | — | — | — |
| Gross profit | −40.0% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ONCO quarterly EPS vs estimates
Onconetix beat the analyst EPS estimate in 2 of the last 4 quarters. Next report: November 12, 2026.
ONCO income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $815,371 | $2.5M | $58,465 | $0 | $0 | $0 | $0 |
| Cost of revenue | $182,458 | $1.5M | $1.2M | $6,752 | $4,890 | $3,056 | $573 |
| Gross profit | $632,913 | $1.1M | −$1.1M | −$6,752 | −$4,890 | −$3,056 | −$573 |
| Research & development | $66,133 | $154,359 | $1.9M | $4.1M | $1.3M | $524,908 | $60,174 |
| Sales, general & admin | $7.0M | $11.2M | $16.8M | $9.4M | $2.1M | $1.1M | — |
| Total operating expenses | $7.0M | $57.5M | $34.9M | $13.5M | $3.4M | $1.6M | $879,659 |
| Operating income | −$6.3M | −$56.5M | −$36.0M | −$13.5M | −$3.4M | −$1.6M | −$880,230 |
| Interest income | $2 | $18 | $0 | — | $0 | $22,603 | $58,317 |
| Interest expense | $751,005 | $1.4M | $671,625 | $0 | — | — | — |
| Income before taxes | −$14.0M | −$59.7M | −$37.4M | −$13.4M | −$3.4M | −$1.6M | −$821,915 |
| Income taxes | $525 | −$1.0M | −$12,593 | −$61,410 | −$4 | −$203,241 | −$3 |
| Net income | −$14.0M | −$58.7M | −$37.4M | −$13.4M | −$3.4M | −$1.6M | −$821,915 |
| EBITDA | −$13.3M | −$57.6M | −$36.7M | −$13.4M | −$3.4M | −$1.6M | −$821,342 |
| EPS (diluted) | −$55.87 | −$2443.99 | −$87316.05 | −$1598.70 | −$0.17 | −$0.53 | — |
| Gross margin | 77.6% | 41.8% | −1,927.9% | — | — | — | — |
| Operating margin | −778.2% | −2,238.0% | −61,634.5% | — | — | — | — |
| Net margin | −1,721.0% | −2,325.2% | −63,986.5% | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $17,120 | $21,457 | $303,596 | $303,651 | $106,494 | $101,630 | $711,976 | $406,859 | $704,848 | $700,433 | $58,465 | $0 |
| Cost of revenue | $12,817 | $23,112 | $55,912 | $34,757 | $35,991 | $55,798 | $52,008 | $301,445 | $604,132 | $511,433 | — | $1,617 |
| Gross profit | $4,303 | −$1,655 | $247,684 | $268,894 | $70,503 | $45,832 | $659,968 | $105,414 | $100,716 | $189,000 | — | −$1,617 |
| Research & development | $3,440 | $50,818 | $24,293 | $3,211 | $111,670 | $24,455 | $290 | $109,365 | $3,680 | $48,964 | $198,921 | $219,238 |
| Sales, general & admin | $2.2M | $2.0M | $1.5M | $2.3M | $1.5M | $1.7M | $2.6M | $2.6M | $2.2M | $8.6M | $6.4M | $4.3M |
| Total operating expenses | $2.7M | $2.1M | $1.5M | $2.3M | $1.4M | $1.7M | $2.7M | $2.8M | $13.7M | $11.3M | $7.4M | $4.5M |
| Operating income | −$2.7M | −$2.1M | −$1.3M | −$2.1M | −$1.3M | −$1.7M | −$2.0M | −$2.6M | −$13.6M | −$11.1M | −$7.4M | −$4.5M |
| Interest expense | $4,389 | $2,244 | $4,247 | $300,069 | $223,097 | $223,592 | $248,349 | $384,958 | $361,315 | $413,056 | $188,532 | $269,097 |
| Income before taxes | −$2.9M | −$4.2M | $5.7M | −$8.8M | −$2.4M | −$8.5M | −$30.4M | −$3.9M | −$14.3M | −$11.2M | −$22.4M | −$5.3M |
| Income taxes | — | — | $525 | — | — | −$917,997 | — | −$56,384 | $50,768 | −$121,567 | — | $269,097 |
| Net income | −$2.9M | −$4.2M | $5.7M | −$8.8M | −$2.4M | −$8.5M | −$29.4M | −$3.8M | −$14.3M | −$11.1M | −$22.4M | −$5.3M |
| EBITDA | −$2.9M | −$4.2M | $5.7M | −$8.5M | −$2.1M | −$8.3M | — | −$3.3M | −$13.7M | −$10.6M | — | −$5.1M |
| EPS (diluted) | −$1.28 | $0.00 | $0.00 | −$6.25 | −$4.18 | −$45.44 | −$2.93 | −$249.08 | −$2191.49 | −$0.50 | −$3404.00 | −$52700.03 |
| Gross margin | 25.1% | −7.7% | 81.6% | 88.6% | 66.2% | 45.1% | 92.7% | 25.9% | 14.3% | 27.0% | — | — |
| Operating margin | −15,950.9% | −9,748.8% | −422.1% | −681.5% | −1,259.6% | −1,626.3% | −277.0% | −650.3% | −1,931.6% | −1,582.2% | −12,591.0% | — |
| Net margin | −16,748.3% | −19,643.4% | 1,867.5% | −2,892.7% | −2,227.8% | −8,408.8% | −4,134.7% | −940.7% | −2,029.8% | −1,587.4% | −38,229.5% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ONCO's financial statements (latest annual report filed March 13, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ONCO financial results
In fiscal year 2025 (ended December 31, 2025), Onconetix reported revenue of $0.8 million, down 67.7% from the year before. It had a net loss of $14.0 million, a net profit margin of −1,721.0%. Diluted earnings per share came to −$55.87.
See the ONCO stock overview for the latest quote and news, or the ONCO chart for price history and technical indicators.
ONCO income statement FAQ
What is Onconetix's annual revenue?
Onconetix reported total revenue of $0.8 million for fiscal year 2025, which ended on December 31, 2025. That was down 67.7% from $2.5 million the previous year.
Is Onconetix profitable?
No. Onconetix reported a net loss of $14.0 million in fiscal 2025, a net profit margin of −1,721.0%; its operating margin was −778.2%.
What is Onconetix's gross margin?
Onconetix's gross margin was 77.6% in fiscal 2025: for every $100 of revenue, Onconetix kept $78 after the direct cost of its products and services.
How much does Onconetix spend on research and development?
Onconetix spent $0.1 million on research and development in fiscal 2025, 8.1% of revenue.
What are Onconetix's earnings per share?
Onconetix earned $-55.87 per diluted share in fiscal 2025, compared with $-2443.99 a year earlier.
When will Onconetix report its next earnings?
Onconetix is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
When does Onconetix's fiscal year end?
Onconetix's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 13, 2026.